Showing results (181-190 of 197) with videos related to

Sort By:
Pageof 20
JAMA Network Open|October 21, 2020
Effect of the Wingman-Connect Upstream Suicide Prevention Program for Air Force Personnel in Training: A Cluster Randomized Clinical TrialPeter A Wyman, Anthony R Pisani, C Hendricks Brown, et al.
Translational Neurodegeneration|May 1, 2022
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendationsFederico Rodriguez-Porcel, Kathryn A Wyman-Chick, Carla Abdelnour Ruiz, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|December 16, 2024
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodiesKathryn A Wyman-Chick, Matthew J Barrett, Michael J Miller, et al.
Bioorganic & Medicinal Chemistry Letters|January 2, 2009
New quinoline NK3 receptor antagonists with CNS activityPaul W Smith, Paul A Wyman, Peter Lovell, et al.
Biology Letters|December 7, 2006
Benefits of organic farming to biodiversity vary among taxaR J Fuller, L R Norton, R E Feber, et al.
Neurology and Therapy|May 8, 2024
Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for CliniciansKathryn A Wyman-Chick, Parichita Chaudhury, Ece Bayram, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2010
The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonistsDale J Johnson, Ian T Forbes, Steve P Watson, et al.
Biology Letters|December 7, 2006
Effects of genetically modified herbicide-tolerant cropping systems on weed seedbanks in two years of following cropsL G Firbank, P Rothery, M J May, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2022
Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial designJon B Toledo, Carla Abdelnour, Rimona S Weil, et al.
Neuropharmacology|December 5, 2003
Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonistM J Gunthorpe, H K Rami, J C Jerman, et al.
Pageof 20